LLY

1,080.08

+0.19%↑

JNJ

231.67

+0.5%↑

ABBV

215.18

+1.2%↑

UNH

381.43

+0.86%↑

MRK

120.6

-0.02%↓

LLY

1,080.08

+0.19%↑

JNJ

231.67

+0.5%↑

ABBV

215.18

+1.2%↑

UNH

381.43

+0.86%↑

MRK

120.6

-0.02%↓

LLY

1,080.08

+0.19%↑

JNJ

231.67

+0.5%↑

ABBV

215.18

+1.2%↑

UNH

381.43

+0.86%↑

MRK

120.6

-0.02%↓

LLY

1,080.08

+0.19%↑

JNJ

231.67

+0.5%↑

ABBV

215.18

+1.2%↑

UNH

381.43

+0.86%↑

MRK

120.6

-0.02%↓

LLY

1,080.08

+0.19%↑

JNJ

231.67

+0.5%↑

ABBV

215.18

+1.2%↑

UNH

381.43

+0.86%↑

MRK

120.6

-0.02%↓

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

19.76 -0.2

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.63

Massimo

20.3

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+103.11% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-77M 1.8B
Apertura precedente	19.96
Chiusura precedente	19.76

Notizie sul Sentiment di mercato

By Acuity

50%

154 / 344 Classifica in Healthcare

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 mag 2026, 16:52 UTC

Principali Notizie su Eventi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q EPS $11.61 >WEBC

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q Sales $179.6M >WEBC

26 mag 2026, 21:48 UTC

Discorsi di Mercato

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mag 2026, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

26 mag 2026, 20:58 UTC

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 19:22 UTC

Discorsi di Mercato

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mag 2026, 19:17 UTC

Discorsi di Mercato

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mag 2026, 18:56 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mag 2026, 18:03 UTC

Discorsi di Mercato

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mag 2026, 17:42 UTC

Discorsi di Mercato

Grains Await Fresh Trading Catalyst -- Market Talk

26 mag 2026, 17:33 UTC

Discorsi di Mercato

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mag 2026, 17:21 UTC

Discorsi di Mercato

Canada Faces a Labor Market Squeeze -- Market Talk

26 mag 2026, 16:52 UTC

Discorsi di Mercato

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mag 2026, 16:43 UTC

Discorsi di Mercato

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mag 2026, 16:24 UTC

Discorsi di Mercato

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mag 2026, 16:21 UTC

Discorsi di Mercato

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

26 mag 2026, 16:16 UTC

Discorsi di Mercato

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mag 2026, 16:01 UTC

Discorsi di Mercato

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mag 2026, 15:21 UTC

Discorsi di Mercato

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

103.11% in crescita

Previsioni per 12 mesi

Media 40.5 USD 103.11%

Alto 57 USD

Basso 29 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

154 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.